Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 60
- Registration Number
- NCT02904954
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
- Conditions
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2022-07-29
- Target Recruit Count
- 17
- Registration Number
- NCT02901548
- Locations
- 🇺🇸
Mount Sinai Medical Center Miami, Miami Beach, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 55
- Registration Number
- NCT02899195
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 2
- Registration Number
- NCT02898116
- Locations
- 🇺🇸
Research Facility, New York, New York, United States
Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder
- Conditions
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Monika Joshi, MD
- Target Recruit Count
- 26
- Registration Number
- NCT02891161
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)
- Conditions
- Interventions
- First Posted Date
- 2016-08-31
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT02885727
Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.
- Conditions
- Interventions
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 41
- Registration Number
- NCT02882308
- Locations
- 🇬🇷
Euromedica General Clinic of Thessaloniki, Thessaloníki, Thessaloniki, Greece
🇬🇷University Hospital "Attikon", 2nd Department of Internal Medicine, Division of Oncology, Athens, Greece
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2024-01-05
- Target Recruit Count
- 47
- Registration Number
- NCT02879617
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Simmons Comprehensive Cancer Center - UT Southwestern Medical Center, Dallas, Texas, United States
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 140
- Registration Number
- NCT02879162
- Locations
- 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.